Literature DB >> 35771734

Interim Analysis of Acute Hepatitis of Unknown Etiology in Children Aged <10 Years - United States, October 2021-June 2022.

Jordan Cates, Julia M Baker, Olivia Almendares, Anita K Kambhampati, Rachel M Burke, Neha Balachandran, Eleanor Burnett, Caelin C Potts, Sarah Reagan-Steiner, Hannah L Kirking, David Sugerman, Umesh D Parashar, Jacqueline E Tate.   

Abstract

On April 21, 2022, CDC issued a health advisory† encouraging U.S. clinicians to report all patients aged <10 years with hepatitis of unknown etiology to public health authorities, after identification of similar cases in both the United States (1) and Europe.§ A high proportion of initially reported patients had adenovirus detected in whole blood specimens, thus the health advisory encouraged clinicians to consider requesting adenovirus testing, preferentially on whole blood specimens. For patients meeting the criteria in the health advisory (patients under investigation [PUIs]), jurisdictional public health authorities abstracted medical charts and interviewed patient caregivers. As of June 15, 2022, a total of 296 PUIs with hepatitis onset on or after October 1, 2021, were reported from 42 U.S. jurisdictions. The median age of PUIs was 2 years, 2 months. Most PUIs were hospitalized (89.9%); 18 (6.1%) required a liver transplant, and 11 (3.7%) died. Adenovirus was detected in a respiratory, blood, or stool specimen of 100 (44.6%) of 224 patients.¶ Current or past infection with SARS-CoV-2 (the virus that causes COVID-19) was reported in 10 of 98 (10.2%) and 32 of 123 (26.0%) patients, respectively. No common exposures (e.g., travel, food, or toxicants) were identified. This nationwide investigation is ongoing. Further clinical data are needed to understand the cause of hepatitis in these patients and to assess the potential association with adenovirus.

Entities:  

Mesh:

Year:  2022        PMID: 35771734     DOI: 10.15585/mmwr.mm7126e1

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  2 in total

1.  Potential protective benefits of Schisandrin B against severe acute hepatitis in children during the COVID-19 pandemic based on a network pharmacology analysis.

Authors:  Yanhua Fang; Lingling Zhang; Zhe Wang; Ruoyu Wang; Shanshan Liang
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

2.  Paediatric acute liver failure: Confirm the outbreak, find the cause and explore the mechanisms.

Authors:  Audrey Coilly; Didier Samuel
Journal:  United European Gastroenterol J       Date:  2022-09-12       Impact factor: 6.866

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.